PDC and chronic kidney disease: To identify potential additional unintended, non-beneficial effects associated with long-term increasing Hgb levels through genetically proxied therapeutic PHD inhibition, we tested the EGLN-specific Hgb GRS for association with 923 traits in up to 451 099 unrelated European UKB individuals regardless of CKD status.